Y el nuevo fichaje:
...reporting directly to Patrick J. McEnany, Catalyst’s Chairman and CEO. Mr. Ailinger will be responsible for leading the Company’s business development and corporate strategy initiatives, including licensing and partnering discussions.
We are delighted to add David to our senior management team at such a transformative time for our Company,” said Mr. McEnany. “Dave is a seasoned veteran with 15 years of business development experience with branded drugs. He brings valuable new skills to Catalyst at a time when business development is a core strategic focus for us, as we look to broaden our portfolio of commercial products, our pipeline of late-stage development programs, and our global footprint.” “I am excited to join Catalyst as the Company continues to make an impact for those suffering from rare diseases,” said David Ailinger. “I look forward to working with the Catalyst team as we seek to grow our business and bring innovative therapies to patients worldwide.” Mr. Ailinger most recently served as Senior Director of Corporate Development at Impax Laboratories, where he was responsible for business development activities for specialty products, including the identification, evaluation, negotiation and execution of business development activities. Prior to joining Impax, Mr. Ailinger was Executive Director of global business development at Actavis (formerly Watson Pharmaceuticals). At Actavis, he was responsible for leading global brand business development initiatives. Prior to joining Actavis, Mr. Ailinger was a director of business development and licensing at Teva Pharmaceuticals, previously Barr Laboratories, where he performed a series of roles in corporate and business development across multiple therapeutic areas.
«Después de nada, o después de todo/ supe que todo no era más que nada.»